Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Racecadotril is an antidiarrheal medication that acts as a peripheral enkephalinase inhibitor. It is a prodrug that, after oral administration, is rapidly converted to its active metabolite thiorphan. Thiorphan inhibits the enzyme enkephalinase (also known as neutral endopeptidase) in the intestinal epithelium, protecting endogenous enkephalins from degradation. Enkephalins activate δ opioid receptor on enterocytes, leading to reduced cyclic adenosine monophosphate (cAMP) synthesis and decreased secretion of water and electrolytes into the gastrointestinal lumen. This mechanism reduces diarrhea-related hypersecretion without affecting intestinal motility or transit time, distinguishing it from μ-opioid receptor agonists like loperamide. Racecadotril does not cross the blood–brain barrier at therapeutic doses and has no effect on basal secretion or gastrointestinal transit[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on racecadotril.